Amylin's Long-Awaited Therapy For Lipodystrophy Goes to FDA
By Catherine Shaffer
Wednesday, April 4, 2012
Nearly eclipsed by the lengthy approval process for Bydureon (exenatide once-weekly), Amylin Pharmaceuticals Inc.'s metreleptin (recombinant methionyl human leptin) in diabetes lipodystrophy may soon get its moment in the sun.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.